Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice

Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice

Abstract Dipeptidyl peptidase IV (DPP-IV) inhibitors improve glycemic control by prolonging the action of glucagon-like peptide-1 (GLP-1). In contrast to GLP-1 analogues, DPP-IV inhibitors are weight-neutral. DPP-IV cleavage of PYY and NPY gives rise to PYY3-36 and NPY3-36 which exert potent anorect...

Full description

Bibliographic Details
Main Authors: Henrik H. Hansen, Rikke V. Grønlund, Tamara Baader-Pagler, Peter Haebel, Harald Tammen, Leif Kongskov Larsen, Jacob Jelsing, Niels Vrang, Thomas Klein
Format: Article
Language:English
Published: Nature Publishing Group 2021-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-87539-7

Internet

https://doi.org/10.1038/s41598-021-87539-7

Similar Items